ENGLEWOOD, Colo., Nov. 2, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public offering of 5,735,000 shares of its common stock and warrants to purchase up to an aggregate of 6,020,245 shares of its common stock at a combined public offering price of $1.50 per share and related warrant, including 285,245 warrants sold pursuant to the partial exercise of the underwriters' over-allotment option at a per warrant purchase price of $0.01. Joseph Gunnar & Co., LLC and Feltl and Company acted as joint book-running managers for the offering and Fordham Financial Management, Inc. acted as lead manager for the offering. The company intends to use the net proceeds from the offering to fund the final upfront payment to Acerus Pharmaceuticals under the license and supply agreement entered into on April 22, 2016, to acquire exclusive rights to Natesto; further commercialize Natesto, ProstaScint and Primsol; fund the remaining clinical development activities for MiOXSYS to enable FDA clearance; and working capital for general corporate and administrative expenses. The securities were sold pursuant to an effective registration statement on Form S-1 (File No. 333-213738), as amended, previously filed with the Securities and Exchange Commission (SEC). The final prospectus related to the offering was filed with the SEC on October 28, 2016. Copies of the final prospectus are on the SEC's website located at http://www.sec.gov and may also be obtained from Joseph Gunnar & Co, LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: email@example.com or Feltl and Company at firstname.lastname@example.org. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.